Cocrystal Pharma Statistics
Share Statistics
Cocrystal Pharma has 10.17M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 10.17M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 13.85% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 37 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 6.15K, so 0.06% of the outstanding
shares have been sold short.
| Short Interest | 6.15K |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.17 and the forward
PE ratio is -0.61.
Cocrystal Pharma's PEG ratio is
0.
| PE Ratio | -1.17 |
| Forward PE | -0.61 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.16 |
| P/FCF Ratio | -1.25 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cocrystal Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.77,
with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.77 |
| Quick Ratio | 4.77 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | -0.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,591,272.73 |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -10.29% in the
last 52 weeks. The beta is 2.13, so Cocrystal Pharma's
price volatility has been higher than the market average.
| Beta | 2.13 |
| 52-Week Price Change | -10.29% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 54.78 |
| Average Volume (20 Days) | 22,160 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.88M |
| Net Income | -17.5M |
| EBITDA | -17.43M |
| EBIT | -17.88M |
| Earnings Per Share (EPS) | -1.72 |
Full Income StatementBalance Sheet
The company has 9.86M in cash and 1.81M in
debt, giving a net cash position of 8.05M.
| Cash & Cash Equivalents | 9.86M |
| Total Debt | 1.81M |
| Net Cash | 8.05M |
| Retained Earnings | -333.42M |
| Total Assets | 13.46M |
| Working Capital | 9.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -16.48M
and capital expenditures -8K, giving a free cash flow of -16.49M.
| Operating Cash Flow | -16.48M |
| Capital Expenditures | -8K |
| Free Cash Flow | -16.49M |
| FCF Per Share | -1.62 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
